Daratumumab

證據等級: L5

預測適應症: 10 個

Daratumumab: From Multiple Myeloma to Indolent Plasma Cell Myeloma

One-Sentence Summary

Daratumumab is a human IgG1κ monoclonal antibody targeting CD38, approved internationally for the treatment of multiple myeloma but not yet marketed in Taiwan. The TxGNN model predicts it may be effective for Indolent Plasma Cell Myeloma (smouldering multiple myeloma), with 1 clinical trial (indirect evidence) and 5 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Multiple Myeloma (internationally approved; not marketed in Taiwan)
Predicted New Indication	Indolent Plasma Cell Myeloma
TxGNN Prediction Score	98.13%
Evidence Level	L3
Taiwan Market Status	✗ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, daratumumab is a human anti-CD38 IgG1κ monoclonal antibody that binds to CD38 — a transmembrane glycoprotein highly and uniformly expressed on the surface of malignant plasma cells. Upon binding, it triggers multiple immune-mediated killing mechanisms including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and direct apoptosis induction. Its efficacy in active multiple myeloma has been extensively validated across multiple Phase 3 trials.

Indolent plasma cell myeloma (synonymous with smouldering multiple myeloma, SMM) represents the biologically immediate precursor state to active multiple myeloma. The malignant plasma cells in SMM express CD38 at equally high density as those in active disease — meaning daratumumab’s molecular target is fully intact in this earlier-stage condition. PMID 28915615 directly characterises CD38 expression across the myeloma bone marrow niche by flow cytometry and immunohistochemistry, and explicitly discusses the biological rationale for anti-CD38 immunotherapy in plasma cell disorders at the indolent monoclonal stage.

The TxGNN prediction score of 98.13% reflects this near-perfect mechanistic alignment. Notably, the AQUILA Phase 3 clinical trial (daratumumab monotherapy versus active monitoring in intermediate- and high-risk SMM) has already reported a statistically significant progression-free survival benefit, though this landmark data is not captured in the current Evidence Pack. The clinical trajectory from SMM to active MM is well-defined, and early intervention to delay or prevent transformation represents a logical and high-value therapeutic opportunity.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04136756	Phase 1	Completed	30	Dose escalation study of NKTR-255 (an IL-15 pathway immunomodulator) in relapsed/refractory haematological malignancies; daratumumab SC (DARZALEX FASPRO™) is used as a combination partner in one dosing arm. Daratumumab is not the primary investigational agent — indirect relevance only as a background combination drug in the same disease population.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28915615	2017	Translational/Mechanistic Study	Oncotarget	First systematic characterisation of CD38 expression across the myeloma bone marrow niche using flow cytometry and immunohistochemistry in a cohort including indolent monoclonal plasma cell conditions; provides direct mechanistic rationale for anti-CD38 immunotherapy (daratumumab) in the plasma cell disease continuum
41571958	2026	Review / Clinical Guideline	Nature Reviews Clinical Oncology	Comprehensive review of diagnosis, risk stratification and management of smouldering multiple myeloma; covers evolving treatment paradigms including the shift toward early intervention strategies for intermediate- and high-risk SMM
40257478	2025	Case Report	Annals of Hematology	Paraneoplastic leukocytoclastic vasculitis as a rare initial presentation of smoldering IgG kappa myeloma; illustrates the systemic morbidity that can arise even during the indolent phase, reinforcing the clinical rationale for earlier treatment intervention
32736600	2020	Case Report	BMC Gastroenterology	Crystal storing histiocytosis secondary to indolent multiple myeloma presenting as a colonic mass; demonstrates that indolent plasma cell myeloma can cause significant end-organ complications, supporting the case for effective targeted therapy at this earlier disease stage
34514307	2021	Case Report	European Heart Journal Case Reports	Concomitant aortic valve papillary fibroelastoma and cardiac AL amyloidosis; highlights irreversible end-organ damage arising from plasma cell disorders, underscoring the potential value of early daratumumab-based intervention before transformation to active disease

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — Anti-CD38 human IgG1κ monoclonal antibody (Immunotherapy)
Myelosuppression Risk	Moderate — neutropenia, thrombocytopenia, and anaemia reported, particularly in combination regimens (e.g., with bortezomib or lenalidomide); lower risk as monotherapy
Emetogenicity Classification	Low — as a biologic, primary acute adverse effect is infusion-related reactions (IRR), not nausea/vomiting
Monitoring Items	CBC with differential (frequently during early cycles), liver and renal function, serum immunoglobulins; vital signs monitoring during infusions for IRR; type and screen (daratumumab interferes with indirect antiglobulin tests)
Handling Protection	Standard aseptic biologic preparation protocols apply; not classified as a conventional cytotoxic, but institutional monoclonal antibody handling procedures are required

Safety Considerations

Please refer to the SmPC for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic rationale is exceptionally strong — CD38 is daratumumab’s direct molecular target and is uniformly expressed on plasma cells throughout the disease continuum from SMM to active myeloma. Real-world Phase 3 trial evidence (AQUILA trial) already supports this application and is anticipated to elevate the evidence level to L1 once formally incorporated into the Evidence Pack.

To proceed, the following is needed:

Retrieve and formally document the AQUILA Phase 3 trial results to upgrade evidence level from L3 to L1
Obtain Taiwan SmPC equivalent (or reference the EMA/FDA SmPC) to complete key warnings, contraindications, and drug interaction profiling — currently all flagged as data gaps
Assess TFDA regulatory pathway: daratumumab has no Taiwan authorisation; evaluate filing strategy, compassionate use, or clinical trial application
Establish patient selection criteria — treatment benefit is most clearly established in intermediate- to high-risk SMM (per 2020 IMWG risk model); low-risk SMM patients may not require intervention
Note daratumumab’s known interference with indirect antiglobulin tests (blood bank crossmatching); institutional protocols must be in place before clinical use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.